Ultime notizie per Genpact (NYSE:G) Azioni

Genpact

Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.

Genpact Ltd

Gravity - United States Dollar

Cambria Global Asset Allocation ETF

ISH GLB AAA-AA GVT BND ETF USD ACC

Gabelli Equity Trust, Inc. (The) Common Stock

Gabelli Equity Trust Inc

GEORGIA BANCSHARES INC by Georgia Bancshares, Inc.

Georgia Bancshares Inc

German American Bancorp, Inc. - Common Stock

German American Bancorp Inc

Gabelli ETFs Trust Gabelli Financial Services Opportunities ETF

GRAND BANK CORPORATION by Grand Bank Corp.

Grand Bank Corp

Gaby Inc Ordinary Shares

Gabelli Equity Trust, Inc. (The) Series G Cumulative Preferred Stock

Gabelli Equity Trust, Inc. (The) Pfd Ser H

Gabelli Equity Trust, Inc. (The) 5.00% Series K Cumulative Preferred Stock

Green Automotive Co Corp

GACW Inc

GADSDEN PROPERTIES INC by Gadsden Properties Inc.

Gadsden Properties Inc

GULF ALTERNATIVE ENGY CRP by Gulf Alternative Energy Corp.

Simplify Exchange Traded Funds Simplify Gamma Emerging Market Bond ETF

GRUPO AEROPORTR CNTRO B by Grupo Aeroportuario del Centro Norte S.A.B. de C.V.

Grupo Aeroportuario del Centro Norte SAB de CV

GA eXpress Inc

GURU APP FACTORY CORP by GURU APP FACTORY CORP

GameFi

GREAT AMER FINCL CORP by Great American Financial Corp.

Great American Financial Corp

Amundi Index Solutions - AMUNDI GLOBAL AGGREGATE BOND ETF

GLOBAL ARENA HLDG INC by Global Arena Holding, Inc.

Global Arena Holding Inc

GAIL INDIA 144A ADR

Gaia Inc

GAIL (INDIA) GDR

GAIL INDIA LTD REG S/GDR by Gail India Ltd.

GAIL (India) Ltd

GAIL INDIA LTD S/ADR 144A by Gail India Ltd.

Gladstone Investment Corporation - Business Development Company

Gladstone Investment Corp

Gladstone Investment Corporation - 8.00% Notes due 2028

Gladstone Investment Corporation - 5.00% Notes Due 2026

Gladstone Investment Corporation - 4.875% Notes due 2028

SPDR SSgA Global Allocation ETF

Galxe - United States Dollar

Gala Games - United States Dollar

GALDERMA GROUP AG U/ADR by GALDERMA GROUP AG

Galderma Group AG

Galleinphi Inc

GALANTAS GOLD CORP by Galantas Gold Corp.

Galantas Gold Corp

Galileo Mining Ltd

Galenica Ltd

Galore Resources Inc

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics Inc

General American Investors, Inc. Common Stock

General American Investors Co Inc

Gambling.com Group Limited - Ordinary Shares

Gambling.com Group Ltd

GUJ AMB CEME GDR

GAMMA COMMUNICATIONS PLC by GAMMA COMMUNICATIONS PLC

Gamma Communications PLC

GOLDEN ARROW MERGER CORP UNIT 1 CL A & 1/3 WT EXP

GameSquare Holdings Inc

GameCredits

Gamelancer Media Corp

GAMCO INVESTORS INC A by GAMCO Investors, Inc.

GAMCO Investors Inc

GREAT AMER FOOD CHAIN INC by Great American Food Chain, Inc. (The)

Great American Food Chain Inc

Amplify ETF Trust Amplify Video Game Tech ETF

General American Investors Company, Inc. Cumulative Preferred Stock

GAN Ltd

Gander Gold Corp

GANDER GOLD CORP by Gander Gold Corporation

Gain Therapeutics Inc

Gap Inc

GOLDEN APPLE OIL&GAS INC by Golden Apple Oil & Gas, Inc.

Golden Apple Oil and Gas Inc

FT Vest U.S. Equity Moderate Buffer ETF - April

Generation Asia I Acquisition Limited - Class A Ordinary Shares

Generation Asia I Acquisition Ltd

Generation Asia I Acquisition Limited

Generation Asia I Acquisition Ltd Units (1 Ord Class A & 1/2 War)

Generation Asia I Acquisition Ltd Warrants (01/01/9999)

GARB-OIL & POWER CORP by Garb Oil & Power Corp.

Garb Oil & Power Corp

Gari Network - United States Dollar

Axcap Ventures Inc Class A

AXCAP VENTURES INC by Axcap Ventures Inc.

Axcap Ventures Inc

iShares MSCI USA Quality GARP ETF

GOLDEN AGRI-RES ORD by Golden Agri-Resources

Golden Agri-Resources Ltd

GOLDEN AGRI-RES UNSP/ADR by Golden Agri-Resources

GALLERY RES LTD by Gallery Resources Limited

Gallery Resources Ltd

GOLDEN ARROW RES CP NEW by Golden Arrow Resource Corp.

Golden Arrow Resources Corp

GASE Energy Inc

General Assembly Holdings Ltd Class A

CANPR TECHNOLOGY LTD by CANPR TECHNOLOGY LTD

NATURGY ENERGY GROUP S A by Naturgy Energy Group SA

Naturgy Energy Group SA

NATURGY ENERGY GRP U/ADR by Naturgy Energy Group SA

StealthGas Inc

Gabelli Automation ETF

NG ENERGY INTL CORP by NG Energy International Corp.

NG Energy International Corp

Marblegate Acquisition Corp. - Class A Common Stock

Marblegate Acquisition Corp

GATE

Gatos Silver Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) price target from $75 to $85. Needham analyst Laura Martin maintained a Buy rating. Reddit shares gained 0.5% to close at $70.77 on Tuesday. <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co raised the price target for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from $90 to $120. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Cytokinetics shares fell 2.1% to close at $54.33 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut the price target for Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from $13 to $9. Baird analyst Joel Beatty maintained a Neutral rating. Sage Therapeutics shares fell 4.3% to close at $6.43 on Tuesday. <a href="https://www.benzinga.com/quote/SAGE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) price target from $79 to $90. Baird analyst Colin Sebastian maintained an Outperform rating. Shopify shares gained 2.1% to close at $82.58 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) price target from $590 to $650. Deutsche Bank analyst Bryan Kraft maintained a Hold rating. Netflix shares gained 2.8% to close at $721.76 on Tuesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital raised The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) price target from $360 to $460. Loop Capital analyst Laura Champine upgraded the stock from Hold to Buy. Home Depot shares gained 1.5% to close at $414.18 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from $60 to $63. Morgan Stanley analyst Meta Marshall maintained an Overweight rating. Ciena rose 2.6% to close at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $564 to $570. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 2.4% to close at $518.35 on Tuesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities raised the price target for Blue Owl Capital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) from $24 to $25. JMP Securities analyst Brian McKenna maintained a Market Outperform rating. Blue Owl Capital shares fell 1.8% to close at $20.35 on Tuesday. <a href="https://www.benzinga.com/quote/OWL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) price target from $38 to $44. Baird analyst David Koning maintained a Neutral rating. Genpact shares fell 1.6% to close at $38.92 on Tuesday. <a href="https://www.benzinga.com/quote/G/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think:
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/e01feb48-33dc-4d9a-8aab-90248ce8208f" alt="" style="width:557px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CIEN

CYTK

NFLX

RDDT

SAGE

SHOP

SPGI

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts' ratings for Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.0, a high estimate of $44.00, and a low estimate of $36.00. Surpassing the previous average price target of $37.71, the current average has increased by 8.72%.
<img src="https://www.benzinga.com/files/images/story/2024/1728475288_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Genpact by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Genpact. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genpact compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Genpact's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Genpact's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/G/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Genpact analyst ratings.</a>
<h2>Get to Know Genpact Better</h2>
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
<h3>Understanding the Numbers: Genpact's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Genpact's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.39%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.37%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Genpact's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.26%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Genpact's ROA stands out, surpassing industry averages. With an impressive ROA of 2.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Genpact's debt-to-equity ratio is below the industry average. With a ratio of 0.8, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Genpact Stock

Baird analyst David Koning maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Neutral and raises the price target from $38 to $44.

Baird Maintains Neutral on Genpact, Raises Price Target to $44

Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages
NEW YORK, Sept. 12, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4252444-1&amp;h=3188330273&amp;u=https%3A%2F%2Fwww.genpact.com%2F&amp;a=Genpact">Genpact</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), a global professional services and solutions firm delivering outcomes that shape the future, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4252444-1&amp;h=249536951&amp;u=https%3A%2F%2Fwww.stada.com%2F&amp;a=STADA">STADA</a>&nbsp;(SAZ.DE), a leading manufacturer of consumer healthcare, generic and specialty pharma medicines, today announced the renewal of a multi-year partnership. The new chapter of innovation is aimed at further derisking, scaling, and simplifying STADA's finance operations to drive competitive advantages.

Genpact And STADA Renew Multi-Year Partnership To Enhance Finance Operations

Accenture plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acn#NYSE">ACN</a>) has seen its stock rise 17% in the past three months, outperforming the industry&#39;s 10.4% growth and the 0.4% uptick in the S&amp;P 500 composite index.
Recently, Accenture broadened its strategic alliance with Unilever (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ul#NYSE">UL</a>) to streamline Unilever&#39;s digital infrastructure and leverage generative AI to enhance efficiency and operational agility. By tapping into Accenture&#39;s expertise, Unilever aims to identify where AI can generate the most significant transformative impact, ultimately yielding higher returns on investment.
<div class="chart_embed">
<h2>Accenture PLC Price</h2>
<h2><img alt="Accenture PLC Price" src="https://staticx-tuner.zacks.com/images/charts/ba/1725875044.png" style="height:300px; width:600px" title="" /></h2>
Accenture PLC price | Accenture PLC Quote
</div>
<h2>GenWizard Platform: A Key Driver of Change</h2>
Under this multi-year collaboration, Unilever will collaborate with Accenture to establish new standards in generative AI-driven productivity across the industry. This involves scaling AI applications that have already demonstrated the ability to cut costs and optimize operations on a global scale.
Accenture will provide Unilever access to its GenWizard platform, designed to fast-track technological and digital product development. The platform, armed with more than 350 patents and ready-to-use tools and frameworks, offers a comprehensive suite of solutions tailored to achieve specific business technology goals. The partnership will allow Unilever to deploy targeted generative AI solutions throughout its operations, driving efficiency, cost reduction and discovering innovative workflows. Ultimately, this collaboration is expected to help Unilever gain a competitive edge in the marketplace.
<h2>Driving Digital Transformation and Competitive Advantage</h2>
Accenture&#39;s collaboration with Unilever marks a strategic move toward strengthening its position as a leader in digital transformation, particularly in the realm of generative AI. The use of Accenture&#39;s GenWizard platform underscores the company&#39;s commitment to providing cutting-edge solutions that enable its clients to achieve operational excellence.
From Unilever&#39;s perspective, the application of generative AI is expected to enhance overall business performance by simplifying its digital core, identifying new efficiencies and scaling successful AI use cases globally. These initiatives are likely to drive significant cost reductions, operational agility and business insights, positioning Unilever to better adapt to an increasingly competitive and technology-driven market.
The partnership also highlights the growing importance of AI in shaping corporate strategies. Companies that harness AI&#39;s potential to streamline operations and improve decision-making will likely gain a competitive edge. This collaboration serves as a testament to the value of long-term investments in AI-driven innovations.
<h2>Zacks Rank and Stocks to Consider</h2>
ACN currently carries a Zacks Rank #4 (Sell).
A couple of better-ranked stocks from the broader Zacks Business Services sector are AppLovin&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) and Genpact (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/g#NYSE">G</a>).
APP currently sports a Zacks Rank of 1 (Strong Buy). The company has a long-term earnings growth expectation of 20%. JAMF delivered a trailing four-quarter earnings surprise of 21.1%, on average.
Genpact carries a Zacks Rank of 2 (Buy) at present. It has a long-term earnings growth expectation of 8.4%.G delivered a trailing four-quarter earnings surprise of 6.9%, on average.
<a href="https://www.zacks.com/stock/news/2333218/accenture-and-unilever-collaborate-on-generative-ai-platform?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2333218">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Mid Cap

Tech

Accenture and Unilever Collaborate on Generative AI Platform

Jefferies analyst Surinder Thind maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Hold and raises the price target from $35 to $40.

Jefferies Maintains Hold on Genpact, Raises Price Target to $40

In the preceding three months, 5 analysts have released ratings for Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Genpact and provided 12-month price targets. The average target is $40.6, accompanied by a high estimate of $43.00 and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 6.28% increase from the previous average price target of $38.20.
<img src="https://www.benzinga.com/files/images/story/2024/1725656411_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Genpact is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Genpact. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genpact compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Genpact's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Genpact's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/G/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Genpact analyst ratings.</a>
<h2>All You Need to Know About Genpact</h2>
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
<h3>Understanding the Numbers: Genpact's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Genpact's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 6.39%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Genpact's net margin excels beyond industry benchmarks, reaching 10.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Genpact's ROE excels beyond industry benchmarks, reaching 5.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Genpact's ROA excels beyond industry benchmarks, reaching 2.46%. This signifies efficient management of assets and strong financial health.
Debt Management: Genpact's debt-to-equity ratio is below the industry average. With a ratio of 0.8, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 5 Analyst Insights On Genpact

JP Morgan analyst Tien-Tsin Huang maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Neutral and raises the price target from $35 to $43.

JP Morgan Maintains Neutral on Genpact, Raises Price Target to $43

Corpay, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cpay#NYSE">CPAY</a>) has had an impressive run over the past six months. Shares have gained 10% against the 1.6% decline of the industry&nbsp;it&nbsp;belongs to and the 11.3% rise of the Zacks S&amp;P 500 composite. 
The company has an expected long-term (three to five years) earnings per share growth rate of 14.1%. Its earnings are expected to register growth of 12% in 2024 and 15.5% in 2025.
<div class="chart_embed">
<h2>Corpay, Inc. Price</h2>
<h2><img alt="Corpay, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/36/1724774345.png" style="height:283px; width:610px" title="" /></h2>
Corpay, Inc. price | Corpay, Inc. Quote
</div>
<h2>Factors That Bode Well for CPAY</h2>
Corpay&#39;s top line continues to grow organically, driven by increased volume and revenues per transaction in its payment programs. The company continues to witness solid organic revenue growth, driven by sales, improving retention and business initiatives. Notably, organic revenue growth was 10%, 13%, 12%, 11%, and 10%, respectively, in 2023, 2022, 2021, 2020 and 2019.
CPAY has been consistently pursuing acquisitions and investments, both domestically in the United States and globally, to increase its customer base, workforce, and operational capabilities and expand its range of services across various industries. The September 2023 acquisition of PayByPhone expanded the company&#39;s vehicle payment solutions for B2B fleet customers in North America and Europe. In 2023, it also acquired Global Reach Group, Mina Digital Limited and Business Gateway AG. These acquisitions marked a significant expansion of CPAY&#39;s product portfolio and geographic presence.
CPAY has a consistent track record of share repurchase. In 2023, 2022, 2021 and 2020, the company repurchased shares worth $686.9 million, $1.41 billion, $1.36 billion and $849.9 million, respectively. Such moves indicate the company&#39;s commitment to create value for shareholders and underline its confidence in its business.
<h2>A Risk for Corpay</h2>
Corpay&#39;s current ratio (a measure of liquidity) at the end of second-quarter 2024 was 1.02, lower than the prior quarter&#39;s 1.07 and the year-ago quarter&#39;s 1.08.&nbsp;A decline in the current ratio&nbsp;does not bode well.
<h2>Zacks Rank and Stocks to Consider</h2>
CPAY currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader Zacks Business Services sector are Genpact (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/g#NYSE">G</a>) and Jamf (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jamf#NASDAQ">JAMF</a>).
Genpact carries a Zacks Rank of 2 (Buy) at present. It has a long-term earnings growth expectation of 8.4%.G delivered a trailing four-quarter earnings surprise of 6.9%, on average.
Jamf currently carries a Zacks Rank of 2. The company has a long-term earnings growth expectation of 57%. JAMF delivered a trailing four-quarter earnings surprise of 15.7%, on average.
<a href="https://www.zacks.com/stock/news/2327881/why-you-should-retain-corpay-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2327881">To read this article on Zacks.com click here.</a>

CPAY

JAMF

Why You Should Retain Corpay Stock in Your Portfolio Now

H&amp;R Block, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrb#NYSE">HRB</a>) has performed exceptionally well in the past year and has the potential to sustain this momentum in the near term. Consequently, if you haven&#39;t taken advantage of its share price appreciation yet, it&#39;s time you add the stock to your portfolio.
<h2>What Makes HRB an Attractive Pick?</h2>
An Outperformer:&nbsp;A glimpse at this consumer services company&#39;s price trend reveals that the stock has had an impressive run over the past year. Shares of H&amp;R Block have gained 61.8%, significantly outperforming the 18.3% rise of the&nbsp;industry&nbsp;it belongs to and the 27.3% rally of the Zacks S&amp;P 500 composite.
<h2>H&amp;R Block, Inc. Price</h2>
<div class="chart_embed">
<h2><img alt="H&amp;R Block, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/18/1724422402.png" style="height:310px; width:600px" title="" /></h2>
H&amp;R Block, Inc. price | H&amp;R Block, Inc. Quote
Solid Rank and VGM Score: H&amp;R Block has a Zacks Rank #1 (Strong Buy) and a VGM Score of B. Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best investment opportunities for investors. Thus, the company is a compelling investment proposition at the moment.
</div>
Northward Estimate Revisions: Two estimates for fiscal 2025 have moved north in the past 30 days versus no southward revision, reflecting analysts&#39; confidence in the company. The Zacks Consensus Estimate for HRB&#39;s fiscal 2025 earnings has moved up nearly 6.7% in the past 30 days.
Strong Growth Prospects: The company has an expected long-term (three to five years) earnings per share growth rate of 12.5%. Its fiscal 2025 earnings are expected to improve 15.2% year over year.
Positive Earnings Surprise History: HRB has an impressive earnings surprise history. The company outpaced the Zacks Consensus Estimate in all the trailing four quarters, delivering an average earnings surprise of 10.8%.
Growth Factors:&nbsp;H&amp;R Block has a five-year strategy called Block Horizons in place. The strategy is focused on using human expertise and technological infrastructure to drive innovation. It aims to build strong relationships with small businesses through Wave and Block Advisors, develop Emerald Card as a consumer-centric, mobile-first solution for the underbanked, and make taxation faster and more personalized by integrating human expertise with digital tools.
Block Horizons is expected to help the company earn sustainable revenues and operating profit growth, improve return on investments, and maintain a strong balance sheet and liquidity position.
We believe that the main drivers of the company&#39;s post-pandemic performance are the digital enablement of its business, client addition and retention in both Assisted and DIY, greater usage of AI, and machine learning for product improvement and expansion in small businesses.
<h2>Other Stocks to Consider</h2>
A couple of other top-ranked stocks from the broader Zacks Business Services sector are Genpact (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/g#NYSE">G</a>) and&nbsp;Jamf (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jamf#NASDAQ">JAMF</a>).
Genpact carries a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 8.4%.G delivered a trailing four-quarter earnings surprise of 6.9%, on average.
Jamf currently carries a Zacks Rank of 2. The company has a long-term earnings growth expectation of 57%. JAMF delivered a trailing four-quarter earnings surprise of 15.7%, on average.
<a href="https://www.zacks.com/stock/news/2326563/here-s-why-h-r-block-hrb-stock-is-a-great-pick-right-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2326563">To read this article on Zacks.com click here.</a>

Here's Why H&R Block Stock is a Great Pick Right Now

Genpact's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) short percent of float has fallen 8.38% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Genpact Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724421613_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Genpact has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Genpact's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Genpact's peer group average for short interest as a percentage of float is 4.76%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Genpact's Recent Short Interest

In the last three months, 4 analysts have published ratings on Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.0, along with a high estimate of $42.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 2.56% increase from the previous average price target of $39.00.
<img src="https://www.benzinga.com/files/images/story/2024/1723489297_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Genpact. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Genpact. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genpact compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Genpact's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Genpact's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/G/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Genpact analyst ratings.</a>
<h2>Get to Know Genpact Better</h2>
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
<h3>Financial Insights: Genpact</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Genpact's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 3.98%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Genpact's net margin is impressive, surpassing industry averages. With a net margin of 10.37%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Genpact's ROE stands out, surpassing industry averages. With an impressive ROE of 5.26%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Genpact's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.46% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Genpact's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.79.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Genpact Analyst Ratings

BMO Capital analyst Keith Bachman maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Market Perform and raises the price target from $38 to $42.

BMO Capital Maintains Market Perform on Genpact, Raises Price Target to $42

Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS <a href="https://www.benzinga.com/quote/G/earnings">guidance above estimates.</a>
Genpact reported quarterly earnings of 79 cents per share which beat the analyst consensus estimate of 72 cents per share. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.14 billion.
&#8220;Following another quarter of better-than-expected results and a robust first half performance, we are raising our earnings expectations for the year,&#8221; said Balkrishan &#8220;BK&#8221; Kalra, Genpact&#8217;s President and CEO. &#8220;Our second quarter results are a testament to the team&#8217;s ability to successfully deliver on our &#8216;3+1 Execution Framework&#8217;. Looking ahead, we will continue to drive execution and lean into innovation, leveraging gen AI and other advanced technologies to deliver superior value for clients and drive productivity for Genpact.&#8221;
Genpact shares gained 16.3% to trade at $37.67 on Friday.
These analysts made changes to their price targets on Genpact following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/topic/mayank-tandon">Needham analyst Mayank Tandon</a> maintained Genpact with a Buy and raised the price target from $40 to $42.</li>
<li>TD Cowen analyst Bryan Bergin maintained Genpact with a Hold and boosted the price target from $35 to $36.</li>
</ul>
Considering buying Genpact stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/09140159/image-1-27-1024x559.png" alt="" class="wp-image-487533" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/09140159/image-1-27-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/09140159/image-1-27-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/09140159/image-1-27-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/09140159/image-1-27.png 1241w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/markets/24/08/40285451/jim-cramer-this-energy-stock-is-a-buy-stay-away-from-dexcom"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40285451/jim-cramer-this-energy-stock-is-a-buy-stay-away-from-dexcom">Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom</a></li>
</ul>

Genpact Analysts Boost Their Forecasts Following Upbeat Earnings

TD Cowen analyst Bryan Bergin maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Hold and raises the price target from $35 to $36.

TD Cowen Maintains Hold on Genpact, Raises Price Target to $36

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) rose sharply during Friday's session after the company reported<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40288024/expedias-q2-triumph-analysts-highlight-vrbo-as-bright-spot-praise-growth-in-busines"> better-than-expected second-quarter financial results.</a>
Expedia Group reported quarterly earnings of $3.51 per share which beat the analyst consensus estimate of $3.06 per share. The company reported quarterly sales of $3.558 billion which beat the analyst consensus estimate of $3.534 billion.
Expedia Group shares jumped 9.4% to $129.02 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) gained 32% to $3.55 after the company reported better-than-expected second-quarter financial results. Also, William Blair upgraded the stock from Market Perform to Outperform.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 31.6% to $33.82 after the company reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares surged 29.5% to $15.80 after the company reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) climbed 26.2% to $33.13 after the company reported better-than-expected second-quarter revenue results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) rose 24.2% to $25.92 after the company reported better-than-expected quarterly financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 20.2% to $9.54 after the company reported better-than-expected second-quarter financial results and issued third-quarter product revenue guidance above estimates.</li>
<li>CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) gained 18.2% to $26.48 after the company reported better-than-expected second-quarter financial results and issued third-quarter non-GAAP EPS guidance above estimates.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 15.6% to $4.2550 after the company reported better-than-expected second-quarter financial results.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) rose 14.9% to $37.23 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 13.7% to $22.19 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) rose 13.4% to $32.99 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 12.2% to $5.35 after the company reported better-than-expected second-quarter financial results. Also, the company announced it hot fired its new rocket engine Archimedes for the first time.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) rose 11.3% to $101.91 after the company reported better-than-expected second-quarter financial results.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) gained 10.6% to $46.31.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose 9.6% to $96.81 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Also, Keybanc and Susquehanna raised their respective price targets on the stock.</li>
<li>DXC Technology Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) climbed 7.2% to $19.64 after the company reported better-than-expected quarterly financial results..</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 5.8% to $894.83.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august">Top 2 Risk Off Stocks That May Implode In August</a></li>
</ul>

Intraday Update

Movers

ADMA

AKAM

BLND

CARG

DOCN

DOCS

EXPE

IOVA

RKLB

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday

WIIM

Genpact shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 and FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.

Needham analyst Mayank Tandon maintains Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) with a Buy and raises the price target from $40 to $42.

Needham Maintains Buy on Genpact, Raises Price Target to $42

Outlook
Genpact's outlook for the third quarter of 2024 is as follows:
<ul>
<li>Total revenue in the range of $1.180 billion to $1.186 billion, representing year-over-year growth of approximately 3.9% to 4.4% as reported, or 4.2% to 4.7% on a constant currency basis.1
<ul>
<li>Digital Operations revenue growth of approximately 3.8% year-over-year and Data-Tech-AI revenue growth of approximately 4.6% year-over-year at the midpoint of the range, as reported.</li>
<li>Digital Operations revenue growth of approximately 4.2% year-over-year and Data-Tech-AI revenue growth of approximately 4.7% year-over-year at the midpoint of the range, on a constant currency basis.1</li>
</ul>
</li>
<li>Gross margin of approximately 35.4%.</li>
<li>Adjusted income from operations margin6 of approximately 17.2%.</li>
</ul>
Genpact's updated outlook for the full year 2024 is as follows:
<ul>
<li>Total revenue in the range of $4.656 billion to $4.701 billion, representing year-over-year growth of approximately 4.0% to 5.0% as reported, or 4.2% to 5.2% on a constant currency basis,1 up from the prior guidance of approximately 2.5% to 3.5% as reported.
<ul>
<li>Digital Operations revenue growth of approximately 5.2% year-over-year and Data-Tech-AI revenue growth of approximately 3.8% year-over-year at the midpoint of the range, as reported, up from the previous midpoints of 3.6% and 2.3%, respectively.</li>
<li>Digital Operations revenue growth of approximately 5.5% year-over-year and Data-Tech-AI revenue growth of approximately 3.9% year-over-year at the midpoint of the range, on a constant currency basis,1 up from the previous midpoints of 4.0% and 2.4%, respectively.</li>
</ul>
</li>
<li>Gross margin of approximately 35.3%.</li>
<li>Adjusted income from operations margin6 of approximately 17.0%.</li>
<li>Adjusted diluted EPS7 in the range of $3.14 to $3.18, up from the prior range of $3.01 to $3.04.</li>
</ul>

Guidance

Genpact Sees Q3 Revenue $1.18B-$1.186B Vs $1.16B Est.; Raises FY24 EPS From $3.01-$3.04 To $3.14-$3.18 Vs $3.03 Est.; Revenue $4.656B-$4.701B Vs $4.62B Est.

Comments

Genpact

Notizie

Ultime notizie per Genpact (NYSE:G) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO